Novel thiazolones for the simultaneous modulation of PPARγ, COX-2 and 15-LOX to address metabolic disease-associated portal inflammation

Novel thiazolones for the simultaneous modulation of PPARγ, COX-2 and 15-LOX to address metabolic disease-associated portal inflammation

A hybrid pharmacophore model, based on structural motifs previously identified by our team, was employed to generate ligands that simultaneously target COX-2, 15-LOX, and PPARγ in the context of metabolic dysfunction-associated fatty liver disease (MAFLD). Notable COX-2 inhibitory activities (IC50 =...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Mai S., El-Shoukrofy (author)
مؤلفون آخرون: Ismail, Azza (author), Elhamammy, Reem H. (author), Abdelhady, Sherien A. (author), Nassra, Rasha (author), Makkar, Monica S. (author), Agami, Mahmoud A. (author), Wahid, Ahmed (author), Nematalla, Hisham A. (author), Sai, Minh (author), Merk, Daniel (author), El-Yazbi, Ahmed F. (author), Belal, Ahmed S.F. (author), Eid, Ali H. (author), Elzahhar, Perihan A. (author)
التنسيق: article
منشور في: 2025
الموضوعات:
Thiazolones
PPARγ
COX-2
15-LOX
Multi-targeting
Liver inflammation
Metabolic diseases
الوصول للمادة أونلاين:http://dx.doi.org/10.1016/j.ejmech.2025.117415
https://www.sciencedirect.com/science/article/pii/S0223523425001801
http://hdl.handle.net/10576/64011
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا

مواد مشابهة